BenevolentAI SPAC Presentation Deck

Identified a now FDA-approved reduces mortality by 38% COVID-19 Drug Identification Custom Workflow Human-guided iterative queries of Knowledge Graph Computational tools enabled scientists to explore the information in the graph. Identified a number of suitable approved drugs through interactive and visual presentations of data Identified baricitinib - an approved rheumatoid arthritis drug - as the strongest candidate in just 48 hours Uncovered previously unknown anti-viral properties Our technology was able to extract and infer new scientific information about baricitinib's combined anti-viral and anti inflammatory mechanism of action Research published in Feb 2020 in THE LANCET & ECMO - extracorporeal membrane oxygenation THE LANCET Infectious Diseases COVID-19 treatment that Lilly Eli Lilly owns baricitinib. Relationship developed into equity investment in Q4 2020 funding round ✔ NOVEL Our tech identified a novel antiviral mechanism from published research data using our proprietary NLP and engineering frameworks ✔ RAPID BenevolentAl introspection tools empowered scientists to rapidly explore and evaluate possible biological narratives & access hypotheses in just 48 hrs ✓ EFFECTIVE Baricitinib is the most effective treatment proven to reduce mortality from COVID-19 in randomised Control Trials: COV-BARRIER trial showed baricitinib reduces mortality by 38% across all patients, and by 46% in ventilated or ECMO patients ✔WORLD-FIRST Of 81 studies using Al to predict drugs to treat COVID-19, ours is the only one to be clinically approved. Now approved as a treatment in the US, Japan & India Benevolent 29

View entire presentation